Q3 2019 13F Holders as of 30 Sep 2019
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250,425,788
-
Total 13F shares
-
64,455,811
-
Share change
-
+64,336,176
-
Total reported value
-
$63,153,426
-
Put/Call ratio
-
67%
-
Price per share
-
$0.98
-
Number of holders
-
81
-
Value change
-
+$63,033,394
-
Number of buys
-
80
-
Number of sells
-
1
Institutional Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q3 2019
As of 30 Sep 2019,
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) was held by
81 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,455,811 shares.
The largest 10 holders included
BROADWOOD CAPITAL INC, BlackRock Inc., VANGUARD GROUP INC, Defender Capital, LLC., Prescott General Partners LLC, STATE STREET CORP, GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, AXA, and Nuveen Asset Management, LLC.
This page lists
81
institutional shareholders reporting positions in this security
for the Q3 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.